BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 11900232)

  • 21. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.
    Liu D; O'Day SJ; Yang D; Boasberg P; Milford R; Kristedja T; Groshen S; Weber J
    Clin Cancer Res; 2005 Feb; 11(3):1237-46. PubMed ID: 15709194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.
    Legha SS; Ring S; Bedikian A; Plager C; Eton O; Buzaid AC; Papadopoulos N
    Ann Oncol; 1996 Oct; 7(8):827-35. PubMed ID: 8922197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biochemotherapy in patients with advanced head and neck mucosal melanoma.
    Bartell HL; Bedikian AY; Papadopoulos NE; Dett TK; Ballo MT; Myers JN; Hwu P; Kim KB
    Head Neck; 2008 Dec; 30(12):1592-8. PubMed ID: 18798304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complex combination biochemotherapy regimen in advanced metastatic melanoma in a non-intensive care unit: toxicity or benefit?
    Hofmann MA; Sterry W; Trefzer U
    Jpn J Clin Oncol; 2007 Mar; 37(3):224-9. PubMed ID: 17472972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Practical guidelines for the management of biochemotherapy-related toxicity in melanoma.
    Buzaid AC; Atkins M
    Clin Cancer Res; 2001 Sep; 7(9):2611-9. PubMed ID: 11555571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.
    O'Day SJ; Boasberg PD; Piro L; Kristedja TS; Wang HJ; Martin M; Deck R; Ames P; Shinn K; Kim H; Fournier P; Gammon G
    Clin Cancer Res; 2002 Sep; 8(9):2775-81. PubMed ID: 12231516
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Combination of dacarbazine, cisplatin and interferon alpha in the treatment of metastatic melanoma].
    Tessier MH; Mansat E; Legoux B; Litoux P; Dreno B
    Ann Dermatol Venereol; 1996; 123(9):538-42. PubMed ID: 9615103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclosporine A, alpha-lnterferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen: a phase II study in advanced melanoma.
    Feun L; Marini A; Moffat F; Savaraj N; Hurley J; Mazumder A
    Cancer Invest; 2005; 23(1):3-8. PubMed ID: 15779861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subcutaneous interleukin-2 and interferon-alpha therapy associated with cisplatin monochemotherapy in the treatment of metastatic melanoma.
    Andrès P; Cupissol D; Guillot B; Avril MF; Drèno B
    Eur J Dermatol; 1998 Jun; 8(4):235-9. PubMed ID: 9649695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II study.
    Stoter G; Shiloni E; Aamdal S; Cleton FJ; Iacobelli S; Bijman JT; Palmer P; Franks CR; Rodenhuis S
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S41-3. PubMed ID: 2697578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases.
    Buzaid AC; Colome M; Bedikian A; Eton O; Legha SS; Papadopoulos N; Plager C; Ross M; Lee JE; Mansfield P; Rice J; Ring S; Lee JJ; Strom E; Benjamin R
    Melanoma Res; 1998 Dec; 8(6):549-56. PubMed ID: 9918417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subcutaneous interleukin-2 and interferon-alpha plus cisplatin with and without prophylactic cimetidine in patients with metastatic malignant melanoma: a phase II study.
    Schmidt H; Geertsen PF; Fode K; Rytter C; Bastholt L; von der Maase H
    Melanoma Res; 2000 Feb; 10(1):66-77. PubMed ID: 10711642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
    Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
    Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
    McClay EF; McClay ME; Monroe L; Baron PL; Cole DJ; O'Brien PH; Metcalf JS; Maize JC
    Br J Cancer; 2000 Jul; 83(1):16-21. PubMed ID: 10883662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outpatient chemoimmunotherapy for the treatment of metastatic melanoma.
    Thompson JA; Gold PJ; Fefer A
    Semin Oncol; 1997 Feb; 24(1 Suppl 4):S44-8. PubMed ID: 9122734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma.
    Pyrhönen S; Hahka-Kemppinen M; Muhonen T; Nikkanen V; Eskelin S; Summanen P; Tarkkanen A; Kivelä T
    Cancer; 2002 Dec; 95(11):2366-72. PubMed ID: 12436444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha.
    Groenewegen G; Bloem A; De Gast GC
    Cancer Immunol Immunother; 2002 Dec; 51(11-12):630-6. PubMed ID: 12439608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
    Kretschmer L; Helmbold P; Emmert S; Marsch WC
    Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting.
    Hess V; Herrmann R; Veelken H; Schwabe M
    Oncology; 2007; 73(1-2):33-40. PubMed ID: 18332650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
    Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
    Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.